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n=85). CGI-I scores improved in 78%, remained stable in 14%, 
and worsened in 8% of patients (n=172) at Month 6, compared 
with 14%, 63% and 24% of patients off treatment (n=80), respec-
tively. The most common AEs were insomnia (n=68 [7%]), head-
ache (n=38 [4%]), and vertigo (n=30 [3%]).
Conclusions: PR-fampridine was well tolerated and associated 
with improvements in QoL over 6-months in French clinical 
practice.
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Background: In the phase 3 CARE-MS I study (NCT00530348), 
alemtuzumab significantly reduced relapse rate over subcutane-
ous interferon beta-1a (SC IFNB-1a), with manageable safety 
over 2 years.
Objectives: Examine 4-year efficacy/safety of alemtuzumab in 
patients treated with alemtuzumab during CARE-MS I, and 2-year 
efficacy/safety in patients switched to alemtuzumab in the exten-
sion study (crossover cohort; NCT00930553).
Methods: In CARE-MS I, treatment-naive patients with active 
RRMS received 2 courses of alemtuzumab (12 mg/day intrave-
nously on 5 consecutive days and on 3 consecutive days 12 
months later) or SC IFNB-1a (44 μg 3 times/week). In the exten-
sion study, patients could receive as-needed alemtuzumab re-
treatment ≥1 year apart or approved disease-modifying therapy 
(DMT). Crossover patients received 2 alemtuzumab courses (5 
days, then 3 days), 12 months apart.
Results: The extension enrolled 349 (95%) alemtuzumab-treated 
patients from the core study. Through 4 years, 73% received only 2 
annual courses, while 21% and 5% received 1 or 2 additional 
courses, respectively; <5% of patients received another DMT dur-
ing extension. Nine patients (3%) discontinued from the study, none 
due to adverse events (AEs). Among SC IFNB-1a–treated patients, 
144 (83%) entered the extension and 132 (92%) received 2 courses 
of alemtuzumab. There were 8 withdrawals (6%) in the crossover 
group during the 2-year extension period, none due to AEs. Efficacy 
and safety data will be reported for both treatment cohorts.
Conclusions: Most patients treated with alemtuzumab did not 
require additional courses or other DMT during the 2-year exten-
sion; study discontinuation rates were low after alemtuzumab 
treatment.
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Background: In the last 2 decades, intensive immunosuppression 
followed by autologous stem cell transplantation (ASCT) has 
been proposed as a possible strategy for treatment of severe 
immune-mediated disorders, including multiple sclerosis (MS).
Objective: To review the outcome of ASCT for MS in Western 
Australia.
Methods: Eligibility criteria for ASCT were (1) progression of 
sustained disability with expanded disability status scale (EDSS) 
score increase of more than 1/10 over a 12 month period, (2) 
advanced MS with threatened loss of ambulation and (3) rapidly 
progressive disease not adequately assessed by EDSS. Stem cell 
mobilization was with cyclophosphamide (CY) 2g/m2 and granu-
locyte-colony stimulating factor 5ug/kg bd. conditioning chemo-
therapy was with CY 50mg/kg and rabbit antithymocyte globulin 
1mg/kg days -5 to -2. Patients were assessed at 3, 6, 12 and 24 
months post-transplant.
Results: Fourteen patients underwent ASCT. Median age was 47 
years; median time from diagnosis to transplant was 12 years. 
Diagnosis at transplant was secondary progressive MS (12), pri-
mary progressive MS (1) and neuromyelitis optica (1). About half 
the cohorts were neurologically stable at 24 months while the 
remainder had clinically relevant neurological deterioration. Two 
patients had meaningful improvement in bladder function. 
Follow-up MRI showed no Gd-enhancing lesions, but two patients 
developed new cerebral lesions on T2 weighted imaging.
Conclusion: In this group of patients with advanced MS, neuro-
logical function 24 months post-ASCT was essentially stable in 
half the cohort while the remainder experienced clinical progres-
sion. It is not possible to conclude whether ASCT altered the natu-
ral history of the disease.
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Background: The CD30 ligand (CD30L)/CD30 axis plays a criti-
cal role in Th1 and Th17 cell differentiation. However the role of 
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